Bristol-Myers v. Biocraft
Executive Summary
Bristol-Myers received a preliminary injunction prohibiting Biocraft from marketing its generic cefadroxil antibiotic on Feb. 28, Bristol announced in a same-day release. Newark Federal Court Judge Dickenson Debevoise determined that the generic product would infringe on Bristol-Myers' crystalline cefadroxil monohydrate patent, due to expire in 2002. Bristol-Myers is seeking a full trial in order to obtain a permanent injunction. Biocraft has 90 days to appeal the ruling to the U.S. Court of Appeals.
You may also be interested in...
QUOTED. 19 April 2021. Jeff Shuren & William Maisel
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
Breakthrough Therapy Designations At US FDA Stay Sluggish In 2021
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
Half Of US FDA’s Breakthrough Therapy Designations Have Resulted In Approval
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.